(Bloomberg) — German factories saw demand collapse in March, when measures to contain the coronavirus brought the economy to a sudden halt. Orders fell 15.6% from the previous month, the most since data collection started in 1991 and more than economists predicted.
UniCredit SpA reported the second loss in a row as provisions related to the coronavirus added to the pain of one-off costs for job cuts and the writedown of its Turkish unit.
Credit Agricole SA is setting aside almost three times the amount it booked a year ago to cover souring loans.
Drug companies stepped up efforts to tackle the virus. Novo Nordisk A/S joined other major drugmakers in reporting surging sales as patients snapped up diabetes medicines. Gilead Sciences Inc. is working to ensure access to a treatment drug in Asia, Europe and the developing world.
Key Developments
- Virus Tracker: global cases pass 3.6 million; deaths top 256,000
- China bristles as Trump pushes virus-from-lab theory
- Covid-19 research groups are being attacked by hackers
- Emerging-market survey sees Latin America biggest virus loser
- Jack Ma’s online bank plans crisis lending spree
- Bailouts spark crisis of confidence in capitalism
- Supply disruptions mask distress in UAE and Saudi Arabia
Subscribe to a daily update on the virus from Bloomberg’s Prognosis team here.
Click VRUS on the terminal for news and data on the coronavirus. See this QuickTake on unanswered questions about the virus.
German Factory Orders Slump With Virus Shutdown Freezing Economy (2:17 p.m. HK)
German factories saw demand collapse in March, when measures to contain the coronavirus brought the economy to a sudden halt.
Orders fell 15.6% from the previous month, the most since data collection started in 1991 and more than economists predicted.
While all sectors were affected, investment goods plunged heavily. The Economy Ministry warned of big declines in production due to the virus.
The larger-than-consensus drop in German factory orders for March illustrates the scale of shutdowns in the euro-area’s biggest economy, writes Bloomberg Economist Jamie Rush.
Novo Joins Other Drugmakers With Gains on Virus Stockpiling (1:47 p.m.
HK)
Novo Nordisk A/S joined other major drugmakers in reporting surging sales as patients snapped up diabetes medicines ahead of coronavirus lockdowns.
- Sales rose 16% to 33.88 billion Danish kroner ($4.92 billion) in the first quarter, the Danish pharma company said Wednesday.
UniCredit Posts $2.9 Billion Loss on Virus Provisions, Charges (1:27 p.m. HK)
UniCredit SpA reported the second loss in a row as provisions related to the coronavirus added to the pain of one off costs for job cuts and the writedown of its Turkish unit.
The net loss totaled 2.71 billion euros ($2.94 billion), as loan-loss provisions climbed to 1.26 billion euros, the Milan-based bank said on Wednesday.
The lender’s main business was resilient in the first quarter, with income from fees and lending beating estimates.
Credit Agricole Sees Provision Surge as Bank Girds for Bad Loans (1pm HK)
Credit Agricole SA is setting aside almost three times the amount it booked a year ago to cover souring loans because of the impact of the coronavirus, the latest lender to try and estimate the damage to its balance sheet from the outbreak.
Provisions in the first three months of the year jumped to 621 million euros ($673 million) from 225 million euros a year earlier to take account of the worsening economic environment, the bank said in a statement on Wednesday.
China Ambassador to U.
S. Urges End to ‘Blame Game’ (12:18 p.m. HK)
China’s ambassador to Washington called for an end to the “blame game” over the coronavirus, in the country’s most high-profile response since U. S. President Donald Trump escalated his criticism of Beijing.
Ambassador Cui Tiankai said in a column published in the Washington Post that allegations blaming China for the outbreak’s spread risked “decoupling” the world’s two largest economies.
Increased suspicions also threatened to hurt U. S.-China cooperation to fight the disease and restart the global economy.
“It is time to end the blame game,” Cui said. “It is time to focus on the disease and rebuild trust between our two countries.”
India Has Record Virus Deaths (10 a.m. HK)
India’s fatalities due to the coronavirus rose 199 to 1,693, the biggest increase so far, while confirmed cases near 50,000, as the country’s citizens emerge from its strict 40-day, nationwide lockdown.
States are still dealing with pockets of unrest after Prime Minister Narendra Modi on Monday partially eased movement curbs across all but the worst infection-hit areas in an attempt to restart its stalled economy.
The economic crisis looks set to be one of Modi’s most serious challenges since he swept to power in 2014, with fears the nation could be heading for its first full-year contraction in more than four decades.
Emerging-Market Survey Sees Latin America as Biggest Virus Loser (8:47 a.m.
HK)
The allure of Latin American assets has all but evaporated in the past three months, underscoring how portfolio allocations are being reshaped by the coronavirus pandemic that has already caused a $3 trillion loss in emerging markets.
A Bloomberg survey of 61 global investors, strategists and traders conducted last month found Latin America is expected to be the laggard for the second half of 2020 in stocks, currencies and bonds.
Asia regained the top spot for fixed-income securities, meaning it ranked highest in all three categories.
Read the last EM survey here.
Mesoblast Doses Patients Remestemcel-L Trial (8:18 a.m. HK)
The first patients have been dosed in the 300-patient randomized placebo-controlled Phase 2/3 trial in the U. S. of Mesoblast’s allogeneic cellular medicine remestemcel-L in Covid-19 infected patients with moderate to severe acute respiratory distress syndrome on ventilator support.
- To view the source of this information click here (Subscription required)
Asia Pacific Firms Raising Capital Amid Virus: Funding Tracker (8 a.m.
HK)
Firms across Asia Pacific are tapping the equity capital markets for more funding as the coronavirus pandemic weighs on the global economy.
Companies in the region have announced or priced a total of $13.3 billion in additional offerings and rights issues of at least $5 million since April 23, according to data compiled by Bloomberg. While Australian firms continue to be the most active, accounting for 15 of the total 34 deals, India’s Reliance Industries Ltd. announced the largest deal: a rights issue of as much as $7 billion.
Sanofi Eyes Early-Stage Vaccine Trials: Reuters (5:51 a.m.
HK)
Sanofi’s Pasteur division hopes to start early-stage trials in September with one covid-19 vaccine candidate and several hundreds of test subjects have been enrolled, Reuters reported, citing executives from the unit.
- Paring up with GlaxoSmithKline Plc, Sanofi will use a protein antigen based on a platform it uses for its influenza vaccine Flublok
- Sanofit is also working with Translate Bio Inc. on another vaccine candidate based on messenger RNA technology, similar to what Pfizer is developing with BioNtech and what Moderna is working on with the U.
S. government, Reuters reported.
Gilead in Talks to Expand Remdesivir Production (5:13 a.m. HK)
Gilead Sciences Inc. is in talks with manufacturers to supply remdesivir, its Covid-19 treatment that’s been cleared by U. S. health regulators for emergency use.
The talks cover production for Europe, Asia and the developing world through 2022, Foster City, California-based Gilead said in a blog post.
It’s also talking with manufacturers in India and Pakistan about manufacturing for developing markets, and about how to license the drug in those markets.
The company promised it will make the compound “accessible and affordable to governments and patients around the world.”
Disney Profit Plunges With Parks Closed (4:20 a.m. HK)
Walt Disney Co.’s second-quarter profit plunged by more than half as the world’s largest entertainment company was bludgeoned on all sides by the coronavirus.
The worst performance by far came from the theme-park division, where operating income tumbled to $639 million from $1.51 billion last year.
Disney’s parks remain shuttered around the world, with the resorts in Asia closed since late January. Profits at the film studio dropped 8% with many theaters shuttered around the world. And cable networks such as ESPN were hurt by an advertising slump in the wake of the coronavirus lockdown. ESPN is especially vulnerable in a world without live sports.
One bright spot was the direct-to-consumer division, which has seen strong growth in subscribers to its new Disney+ streaming service launched in November.
U.
S. Cases Rise Slower Than Week’s Average (4 a.m. HK)
U. S. cases rose 1.9% from the day before to 1.19 million, according to data compiled by Johns Hopkins University and Bloomberg News. That was lower than Monday’s growth rate of 2% and below the average daily increase of 2.6% over the past week. Deaths rose 2.9% to 70,272.
- New cases and deaths in New York both rose 0.7%, according to the Johns Hopkins and Bloomberg News data.
- Florida recorded 37,439 cases, up 1.5% from a day earlier, according to the state’s health department.
Deaths reached 1,471, an increase of 5.1%.
- Hospitalizations in Texas surged to 1,888 from 1,500 a day earlier, the biggest rise in three weeks, according to state health department data. New cases rose 3.2% to 33,369 and fatalities increased by 2.5% to 906.
- California reported 1,275 new cases for Monday, its lowest daily total since April 25. The state had 63 more deaths, up from a three-week low of 39 the prior day.
- Mississippi had the biggest daily increase in cases, which rose 8.7% to 8,208.
White House Weighs Disbanding Task Force (3:30 a.m.
HK)
The White House is discussing disbanding the president’s coronavirus task force, possibly as soon as Memorial Day, Vice President Mike Pence told reporters.
The White House may transition the government’s response to the outbreak to the Federal Emergency Management Agency, Pence said. A time frame for the move could be late May or early June, he added.
But on Tuesday, Pence portrayed the task force as having accomplished its goal as the U.
S. outbreak — the largest in the world — plateaus. There have been nearly 1.2 million cases of Covid-19 and more than 69,000 deaths from the disease, but states are beginning to try to reopen businesses and lift social-distancing regulations as the growth of the outbreak slows.
U. K. Virus Death Toll Overtakes Italy (1:28 a.m. HK)
The U. K.’s coronavirus death toll soared past that of Italy, making it the worst-hit country in Europe, as a top British official expressed regret over the lack of testing in the early stages of the outbreak.
While international comparisons are difficult, official data showed there were 29,427 confirmed coronavirus deaths in the U.
K., with thousands more suspected. The grim milestone will add to the pressure on Boris Johnson’s government, which has faced scrutiny over what some politicians and scientists have warned was a slow response to the pandemic.
Cuomo Warns on Reopening Risks (12:44 a.m. HK)
The number of projected virus deaths in the U. S. has doubled because of governors’ push to reopen, New York Governor Andrew Cuomo said as he warned against prematurely ending lockdowns.
“There’s a cost of reopening quickly,” Cuomo said Tuesday at a press briefing. “The faster we reopen, the lower the economic cost, but the more lives lost.”
The governor cited data from the University of Washington’s Institute for Health Metrics and Evaluation, which has increased its first-wave death projection to more than 130,000 from earlier estimates of about 60,000.
Regeneron Treatment Could Be Out by Fall (12:03 a.m.
HK)
Regeneron Pharmaceuticals Inc. said an experimental antibody treatment for Covid-19 could be available as soon as this fall, an expedited timeline for a drug that’s scheduled to be studied in humans for the first time in June.
To meet the fall timeline will “depend on a lot of factors,” including whether the treatment works as well as hoped, “and there is obviously a lot of risk,” Regeneron Chief Scientific Officer George Yancopoulos said Tuesday on a conference call with investors.
Pfizer Starts U.
S. Trials of Experimental Vaccine (6:50 p.m. HK)
Pfizer Inc. has administered the first U. S. patients with its experimental vaccines to fight the disease caused by the novel coronavirus, part of a bid to shave years off of the typical time it takes to develop a new inoculation. The trials are being conducted at the NYU Grossman School of Medicine and the University of Maryland School of Medicine.
Pfizer and BioNTech are in a race with companies including Johnson & Johnson and Moderna Inc. and academic groups to come up with a safe and effective vaccine against the illness.
The handful of human trials already underway include projects by Moderna, CanSino Biologics Inc., the Beijing Institute of Biotechnology and Inovio Pharmaceuticals Inc.
For more articles like this, please visit us at bloomberg.com
©2020 Bloomberg L. P.
